LSD1-IN-32
LSD1-IN-32 (compound 11e) is a potent LSD1 inhibitor with an IC50 value of 0.99 µM. LSD1-IN-32 inhibits RANKL-induced osteoclastogenesis, bone resorption and F-actin belt formation. LSD1-IN-32 has the potential for the research of osteoporosis.
For research use only. We do not sell to patients.
- Formula: C36H56N2O3Si2
- Molecular Weight:621.01
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Histone Methyltransferase Isoforms
More
Biological Activity
IC50: 0.99 µM (LSD1)[1]
LSD1-IN-32 (compound 11e) (1.25, 2.5, 5 µM) increases the methylation level during osteoclastogenesis in a dose-dependent manner[1].
LSD1-IN-32 (0.25, 0.5, 1, 2, 4 µM) inhibits RANKL-induced osteoclastogenesis, bone resorption and F-actin belt formation[1].
LSD1-IN-32 (2 µM; 0, 1, 2, 4 days) reduces the relative mRNA expression levels induced by RANKL of those genes of Acp5, Nfatc1, Oscar, Dc-stamp, Atp6v0d2, and Ctsk[1].
LSD1-IN-32 (0.5, 1, 2, 4 µM) inhibits the expressions of p-LSD1, p-IκB and p-NFκB in RANKL-induced osteoclastogenesis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:osteoclasts
-
Concentration:2 µM
-
Incubation Time:0, 1, 2, 4 days
-
Result:Reduced the relative mRNA expression levels of those genes (Acp5, Nfatc1, Oscar, Dc-stamp, Atp6v0d2, and Ctsk) induced by RANKL.
-
Cell Line:osteoclasts
-
Concentration:0.5, 1, 2, 4 µM
-
Incubation Time:
-
Result:Dose dependently inhibited the expressions of p-LSD1, p-IκB and p-NFκB in RANKL-induced osteoclastogenesis.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:7-week-old C57BL/6 female mice (OVX (ovariectomy)-induced osteoporosis)[1]
-
Dosage:5, 10 mg/kg
-
Administration:I.p.; daily for four weeks
-
Result:Significantly reduced the loss of the bone mass, reduced OVX-induced osteoclastic bone loss.
Chemical Information
-
Molecular Weight 621.01
-
Formula C36H56N2O3Si2
-
SMILES
O=C(N1CCC(CN[C@H]2[C@H](C3=CC=CC=C3)C2)CC1)/C=C/C4=CC=C(O[Si](C)(C(C)(C)C)C)C(O[Si](C)(C(C)(C)C)C)=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
LSD1-IN-32 Related Classifications
HY-161869 Related Classifications
Powered by Bioz